Friday - July 4, 2025
FDA Grants Accelerated Approval to Lynozyfic for Relapsed/Refractory Multiple Myeloma
July 03, 2025
NORTH HOLLYWOOD, California, July 3 -- The International Myeloma Foundation issued the following news:

* * *

FDA Grants Accelerated Approval to Lynozyfic(TM) (linvoseltamab-gcpt) for Relapsed/Refractory Multiple Myeloma

According to this press release from Regeneron Pharmaceuticals Inc., the "U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic(TM) (linvoseltamab-gcpt) to treat adult patients with relapsed or refractor . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products